- Home
- NNY vs CLLS Comparison
NNY vs CLLS Comparison
Compare NNY & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- CLLS
- Stock Information
- Founded
- NNY 1987
- CLLS 1999
- Country
- NNY United States
- CLLS France
- Employees
- NNY N/A
- CLLS N/A
- Industry
- NNY Investment Managers
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NNY Finance
- CLLS Health Care
- Exchange
- NNY Nasdaq
- CLLS Nasdaq
- Market Cap
- NNY 155.1M
- CLLS 144.4M
- IPO Year
- NNY N/A
- CLLS 2007
- Fundamental
- Price
- NNY $8.18
- CLLS $1.46
- Analyst Decision
- NNY
- CLLS Buy
- Analyst Count
- NNY 0
- CLLS 3
- Target Price
- NNY N/A
- CLLS $6.67
- AVG Volume (30 Days)
- NNY 50.9K
- CLLS 48.8K
- Earning Date
- NNY 01-01-0001
- CLLS 05-12-2025
- Dividend Yield
- NNY 4.04%
- CLLS N/A
- EPS Growth
- NNY N/A
- CLLS N/A
- EPS
- NNY N/A
- CLLS N/A
- Revenue
- NNY N/A
- CLLS $54,747,000.00
- Revenue This Year
- NNY N/A
- CLLS $48.52
- Revenue Next Year
- NNY N/A
- CLLS $5.17
- P/E Ratio
- NNY N/A
- CLLS N/A
- Revenue Growth
- NNY N/A
- CLLS 351.26
- 52 Week Low
- NNY $7.58
- CLLS $1.10
- 52 Week High
- NNY $8.87
- CLLS $2.81
- Technical
- Relative Strength Index (RSI)
- NNY 48.19
- CLLS 48.19
- Support Level
- NNY $8.09
- CLLS $1.46
- Resistance Level
- NNY $8.79
- CLLS $1.60
- Average True Range (ATR)
- NNY 0.23
- CLLS 0.09
- MACD
- NNY -0.01
- CLLS -0.01
- Stochastic Oscillator
- NNY 22.47
- CLLS 39.13
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.